The unpredictable efficacy of current therapies for neuropathic pain may reflect diverse etiological mechanisms operating between, and within, diseases. As descriptions of pain rarely establish specific mechanisms, a tool that can identify underlying causes of neuropathic pain would be useful in developing patient-specific treatments. Rate-dependent depression (RDD), a measure of the change in amplitude of the Hoffman reflex over consecutive stimulations, is attenuated in diabetic rats that also exhibit impaired spinal c-aminobutyric acid (GABA) A receptor function, reduced spinal potassium chloride cotransporter (KCC2) expression, and indices of painful neuropathy. To investigate whether loss of RDD is a reliable indicator of the contribution of spinal GABAergic dysfunction to neuropathic pain, we assessed RDD, tactile allodynia, and formalin-evoked hyperalgesia in 3 models: rats treated acutely with brain-derived neurotrophic factor (BDNF), diabetic rats treated with the BDNF-sequestering molecule tyrosine receptor kinase B/Fc (TrkB/Fc), and rats with paclitaxel-induced neuropathy. Delivery of BDNF to the spinal cord of normal rats produced RDD deficits and features of painful neuropathy associated with disrupted GABA A receptor-mediated inhibitory function and reduced dorsal spinal KCC2 expression. Treating diabetic rats with TrkB/Fc restored RDD and alleviated indices of painful neuropathy. In paclitaxel-treated rats, RDD was not impaired and behavioral indices of neuropathic pain were not associated with spinal GABAergic dysfunction or reduced dorsal spinal KCC2 expression. Our data reveal BDNF as part of the mechanism underlying spinal cord disinhibition caused by altered GABA A receptor function in diabetic rats and suggest that RDD deficits may be a useful indicator of neuropathic pain states associated with spinal disinhibition, thereby revealing specific therapeutic targets. Ó
H-reflex Spinal disinhibition Diabetic neuropathy Pain Taxol neuropathy BDNF a b s t r a c t
The unpredictable efficacy of current therapies for neuropathic pain may reflect diverse etiological mechanisms operating between, and within, diseases. As descriptions of pain rarely establish specific mechanisms, a tool that can identify underlying causes of neuropathic pain would be useful in developing patient-specific treatments. Rate-dependent depression (RDD), a measure of the change in amplitude of the Hoffman reflex over consecutive stimulations, is attenuated in diabetic rats that also exhibit impaired spinal c-aminobutyric acid (GABA) A receptor function, reduced spinal potassium chloride cotransporter (KCC2) expression, and indices of painful neuropathy. To investigate whether loss of RDD is a reliable indicator of the contribution of spinal GABAergic dysfunction to neuropathic pain, we assessed RDD, tactile allodynia, and formalin-evoked hyperalgesia in 3 models: rats treated acutely with brain-derived neurotrophic factor (BDNF), diabetic rats treated with the BDNF-sequestering molecule tyrosine receptor kinase B/Fc (TrkB/Fc), and rats with paclitaxel-induced neuropathy. Delivery of BDNF to the spinal cord of normal rats produced RDD deficits and features of painful neuropathy associated with disrupted GABA A receptor-mediated inhibitory function and reduced dorsal spinal KCC2 expression. Treating diabetic rats with TrkB/Fc restored RDD and alleviated indices of painful neuropathy. In paclitaxel-treated rats, RDD was not impaired and behavioral indices of neuropathic pain were not associated with spinal GABAergic dysfunction or reduced dorsal spinal KCC2 expression. Our data reveal BDNF as part of the mechanism underlying spinal cord disinhibition caused by altered GABA A receptor function in diabetic rats and suggest that RDD deficits may be a useful indicator of neuropathic pain states associated with spinal disinhibition, thereby revealing specific therapeutic targets.
Ó 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Introduction
Neuropathic pain is a common health care problem with low positive treatment outcomes [2,15,49]. One contributing factor is that the etiology of neuropathic pain is varied, and may even differ between patients with the same predisposing condition [11] . Putative mechanisms of neuropathic pain include peripheral sensitization, spinal sensitization, and spinal disinhibition [11] . With many different potential etiologies, it is no surprise that front-line drugs show infrequent and unpredictable efficacy against neuropathic pain [16] . The development of diagnostic techniques to identify specific mechanisms contributing to neuropathic pain may be valuable for developing and refining treatment options for individual patients.
Rate-dependent depression (RDD) is a measure of the decline in amplitude of the spinal Hoffman reflex (H-reflex) over consecutive stimulations that can be assessed in humans and rodents [26, 32, 36, 41] . The magnitude of RDD is indicative of the function of spinal inhibitory systems and, in rodents, is dependent on c-aminobutyric acid (GABA) A receptor-mediated inhibition [29] .
RDD is impaired in rat models of spinal cord injury in which inhibitory interneurons are selectively lost [30, 40] and also in humans with spinal cord injury [5, 26, 50] . This suggests that measurement of RDD in animal models can be directly applicable to the human condition.
In models of neuropathic pain, impaired GABA A receptormediated spinal inhibition has been attributed to reduced spinal activity of the potassium chloride co-transporter (KCC2) [3, 13, 29] . We recently identified both loss of RDD and reduced
